BioDelivery Sciences (BDSI) — This small-cap biopharmaceutical company develops and commercializes therapeutics primarily for pain management and oncology supportive care.
This is a speculative recommendation and not suitable for all investors. It is primarily based on technical analysis since the company is reporting negative earnings. However, in the recently reported second quarter, losses narrowed to $0.05 per share, from $0.36 a year ago. And revenue soared more than 400% year over year to $13.9 million.
On Wednesday, BDSI broke out from a right triangle and double-top on high volume, which was confirmed as it picked up more upside volume and advanced 6% for the day. It also issued a powerful MACD buy signal.
Buy BDSI under $16 with a trading target of $20-plus. A stop-loss order should be placed at $12.75.